We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
11:45
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:00
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
12:15
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
12:30
-
Theatre 1 (Zafir)15 mins
- Cell & Gene Therapy Clinical Pathways
-
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
12:45
-
Theatre 1 (Zafir)45 mins
- Cell & Gene Therapy Clinical Pathways
Understanding the AGORA model:How collaborative, hospital-anchored models like AGORA are reshaping access to gene and cell therapies for rare and ultra-rare diseases. We cannot scale without hospitals ... -
Theatre 2 (Rubi)15 mins
- Operational & Commercial Performance
Why COGS stays stubbornly high: The recurring technical and operational drivers of cost across CGT programme from starting materials and batch failure rates to logistics and facility utilisation. Wher ...
13:00
-
Theatre 2 (Rubi)30 mins
- Operational & Commercial Performance
The cost equation is breaking :Are allogeneic therapies genuinely approaching a manufacturing inflection point and if so, what does that mean for the long-term viability of autologous models that stil ...
13:30
-
Exhibition Hall75 mins
- Networking Break
-
Workshop Room (Rossini 1&2)60 mins
- Workshop
Join VIVEbiotech together with its partners Kiji Therapeutics and Genewity for an interactive panel exploring how lentiviral vector-based therapies are advancing across the full development pathway—fr ...
)
14:45
-
Theatre 1 (Zafir)5 mins
- Plenary
14:50
-
Theatre 1 (Zafir)15 mins
- Plenary
15:05
-
Theatre 1 (Zafir)20 mins
- Plenary
What it takes to build a decentralised CAR-T manufacturing model in practice, and where the original “point-of-care” vision met operational reality. Key lessons from running multi-site GMP manufacturi ...
15:25
-
Theatre 1 (Zafir)40 mins
- Plenary
The next modality frontier is not guaranteed: Which modalities are genuinely emerging as the next growth engines, whether cell therapies face structural headwinds or reinvention, and what lessons Euro ...